A ranking of pharma companies developing new medicines for low- and middle-income countries has revealed that just five companies are responsible for almost two-thirds of projects.
Access to life-saving and life-changing medicines in poorer countries is improving year on year, but there is still more to be done, according to the findings of the 2016 Access to Medicine